Randomized phase IIb trial comparing first-line treatment with aldoxorubicin vs doxorubicin in pts with advanced soft tissue sarcomas. S Chawla
( A10502) ASCO 2015
Tratamiento
Aldoxo
Doxo
Dosis
350mg/m2/3w x6 c
75mg/m2/3w x 6c
N
83
40
mCiclos
6
4
mDosis (equiv)
2100 (1500mg)
300
RR
local/central
21.7/23.8%
5/0%
PFS
5.7m (HR 0.58)
2.8m
pvalor
0.004
Neutropenia
(febril)
40%(15.7)
20(17.5)
Mucositis
10.8%
2.5%
Toxcardiaca
(dism 10%
/<50%)
24%/0%
33%/6%
Doxo
Dox-Ifo
75mg/m2/3w
75mg/m2+ifo 10g/m2/3w
217
215
5
6
375
450
13.6
26.5%
4.6m
7.4m
0.003
37%(13%)
41(45%)
